Intercept Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jerome B. Durso
- Full Time Employees
- 341
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10 Hudson Yards New York City NY United States of America 10001
- IPO Date
- Oct 11, 2012
- CIK
- 0001270073
- Website
- interceptpharma.com
- Similar Companies
- Business
- Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Its flagship product is Ocaliva (obeticholic acid), a first-in-class farnesoid X receptor (FXR) agonist approved for the treatment of PBC, a rare autoimmune liver disease. The company also develops small molecule drugs targeting bile acid receptors to treat chronic fibrotic and metabolic liver diseases. Intercept’s portfolio includes additional clinical-stage candidates such as INT-767 and INT-777, which target FXR and TGR5 receptors for broader therapeutic applications in liver and metabolic disorders. The company operates primarily in the United States, Europe, and Canada and was founded in 2002 with headquarters in New York, New York. Recent major changes include Intercept Pharmaceuticals' acquisition by Italian pharmaceutical firm Alfasigma in a $794 million deal completed in late 2023. This transaction expanded Alfasigma’s presence in gastroenterology and hepatology, notably in the U.S. market, granting it access to Ocaliva and Intercept’s pipeline. In 2025, regulatory challenges arose as Ocaliva was voluntarily withdrawn from the U.S. market following requests from the FDA, with clinical trials involving Ocaliva being placed on hold. Despite setbacks in securing expanded FDA approvals for indications such as nonalcoholic steatohepatitis (NASH), Intercept continues advancing Phase 2 studies for other liver conditions, including a potential first-in-class treatment for severe alcohol-associated hepatitis. Intercept remains a subsidiary of Alfasigma and focuses on evolving its portfolio to address unmet needs in rare and serious liver diseases. This description captures Intercept’s core business activities—manufacture and commercialization of therapeutics for rare liver diseases—along with its key product Ocaliva, pipeline candidates, geographic focus, founding year, headquarters, and the latest strategic acquisition and regulatory developments affecting its operations and product availability.
Intercept Pharma withdraws liver disease drug from US market
US FDA says Intercept's drug can cause liver injury in patients without scarring
US FDA declines full approval for Intercept's liver disease drug
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
FDA advisers vote against confirmatory data for Intercept's liver disease drug
FDA staff raises efficacy concerns over Intercept's liver disease drug
Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today